Stix launched in 2019 as a D2C pregnancy-test maker and has expanded into ovulation tests, prenatal supplements, FDA-cleared UTI diagnostics, pain relief products and preventative supplements. The company sells many products via subscription and lets customers choose delivery frequency. Stix aims to build a full suite of products alongside educational resources and content to guide women through common reproductive and urinary health experiences. The startup emphasizes discrete, easy-to-use diagnostics and has positioned UTI testing as an over-the-counter option to reduce the need for doctor visits. Stix has eight employees, all women, three of whom are people of color, and was co-founded by Cynthia Plotch and Jamie Norwood. Competition includes companies like Modern Fertility, which sells similar reproductive tests and has big-box distribution. Stix sells competitively priced, FDA-cleared pregnancy and ovulation diagnostic tests directly to consumers, with both tests reported as more than 99% accurate. The company emphasizes discretion in delivery (using PayPal billing and a non‑Branded return address) and includes instructional materials with shipments. Stix offers a Stix Library online with educational content on pregnancy, ovulation, birth control and related health topics. Pregnancy tests are sold at $13 for a two-test pack with free shipping; ovulation tests are $17 for a seven-test pack. Co-founder and CEO Cynthia Plotch says the product and experience are focused on learning and education rather than outcomes. The company is a team of three women and plans to use new funding to grow the team and improve diversity.

Total raised

$5M

Funding rounds

2

Latest round

Seed

Latest activity

Apr 2021